» Articles » PMID: 38256151

Coatings for Cardiovascular Stents-An Up-to-Date Review

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jan 23
PMID 38256151
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiovascular diseases (CVDs) increasingly burden health systems and patients worldwide, necessitating the improved awareness of current treatment possibilities and the development of more efficient therapeutic strategies. When plaque deposits narrow the arteries, the standard of care implies the insertion of a stent at the lesion site. The most promising development in cardiovascular stents has been the release of medications from these stents. However, the use of drug-eluting stents (DESs) is still challenged by in-stent restenosis occurrence. DESs' long-term clinical success depends on several parameters, including the degradability of the polymers, drug release profiles, stent platforms, coating polymers, and the metals and their alloys that are employed as metal frames in the stents. Thus, it is critical to investigate new approaches to optimize the most suitable DESs to solve problems with the inflammatory response, delayed endothelialization, and sub-acute stent thrombosis. As certain advancements have been reported in the literature, this review aims to present the latest updates in the coatings field for cardiovascular stents. Specifically, there are described various organic (e.g., synthetic and natural polymer-based coatings, stents coated directly with drugs, and coatings containing endothelial cells) and inorganic (e.g., metallic and nonmetallic materials) stent coating options, aiming to create an updated framework that would serve as an inception point for future research.

Citing Articles

Structure and Functional Characteristics of Novel Polyurethane/Ferrite Nanocomposites with Antioxidant Properties and Improved Biocompatibility for Vascular Graft Development.

Pergal M, Brkljacic J, Vasiljevic-Radovic D, Steinhart M, Ostojic S, Dojcinovic B Polymers (Basel). 2025; 17(2).

PMID: 39861225 PMC: 11768855. DOI: 10.3390/polym17020152.


Physical activity and non-suicidal self-injurious behavior in Chinese adolescents: the chain mediating role of psychological capital and relative deprivation.

Gao Y, Lu C, Zhang X, Han B, Hu H Front Psychiatry. 2024; 15:1509967.

PMID: 39676912 PMC: 11638173. DOI: 10.3389/fpsyt.2024.1509967.


Provinols™, a Polyphenolic Extract of Red Wine, Inhibits In-Stent Neointimal Growth in Cholesterol-Fed Rabbit.

Elbaz M, Roul G, Andriantsitohaina R Pharmaceutics. 2024; 16(10).

PMID: 39458640 PMC: 11510810. DOI: 10.3390/pharmaceutics16101311.


Biofunctional coatings and drug-coated stents for restenosis therapy.

Wen Y, Li Y, Yang R, Chen Y, Shen Y, Liu Y Mater Today Bio. 2024; 29:101259.

PMID: 39391793 PMC: 11465131. DOI: 10.1016/j.mtbio.2024.101259.


Application of PVD coatings in medical implantology for enhanced performance, biocompatibility, and quality of life.

Saad K, Saba T, Rashid A Heliyon. 2024; 10(16):e35541.

PMID: 39220946 PMC: 11363861. DOI: 10.1016/j.heliyon.2024.e35541.


References
1.
Verheye S, Vrolix M, Kumsars I, Erglis A, Sondore D, Agostoni P . The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic Results and 1-Year Clinical Outcomes. JACC Cardiovasc Interv. 2017; 10(20):2029-2037. DOI: 10.1016/j.jcin.2017.06.021. View

2.
Alfonso F, Coughlan J, Giacoppo D, Kastrati A, Byrne R . Management of in-stent restenosis. EuroIntervention. 2022; 18(2):e103-e123. PMC: 9904384. DOI: 10.4244/EIJ-D-21-01034. View

3.
Szott L, Irvin C, Trollsas M, Hossainy S, Ratner B . Blood compatibility assessment of polymers used in drug eluting stent coatings. Biointerphases. 2016; 11(2):029806. PMC: 5014517. DOI: 10.1116/1.4944586. View

4.
Arafat M, Fouladian P, Blencowe A, Albrecht H, Song Y, Garg S . Drug-eluting non-vascular stents for localised drug targeting in obstructive gastrointestinal cancers. J Control Release. 2019; 308:209-231. DOI: 10.1016/j.jconrel.2019.07.001. View

5.
Stiermaier T, Heinz A, Schloma D, Kleinertz K, Danschel W, Erbs S . Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial). Catheter Cardiovasc Interv. 2013; 83(3):418-24. DOI: 10.1002/ccd.25131. View